TABLE 2.

Summary of adverse events occurring in two or more subjects in a cohort^a

Characteristic	Cohort A (100 mg, n = 6)	Cohort B (200 mg, n = 6)	Cohort C (400 mg, n = 6)	Cohort D (800 mg, n = 6)	Cohort E (1,200 mg, n = 6)	Placebo cohort (n = 10)
Abnormal urinalysis	3 (50.0)	3 (50.0)	0	0	0	3 (30.0)
Positive urine leukocyte esterase	1 (16.7)	0	0	3 (50.0)	0	0
Urine WBCs	1 (16.7)	2 (33.3)	0	2 (33.3)	0	0
Urine RBCs	2 (33.3)	0	0	0	0	0
Urine nitrite (+)	2 (33.3)	1 (16.7)	0	1 (16.7)	0	0
Headache	2 (33.3)	1 (16.7)	0	1 (16.7)	2 (33.3)	2 (20)
Dizziness	0	0	0	0	2 (33.3)	0
Musculoskeletal pain	0	1 (16.7)	0	2 (33.3)	2 (33.3)	2 (33.3)
Abdominal pain	0	0	0	2 (33.3)	1 (16.7)	0
Decreased hemoglobin	3 (50.0)	2 (33.3)	1 (16.7)	1 (16.7)	0	0
Increased neutrophils	0	0	0	0	2 (33.3)	0
Increased eosinophils	0	2 (33.3)	1 (16.7)	0	0	0
Decreased serum calcium	1 (16.7)	2 (33.3)	1 (16.7)	0	0	0

^aValues are numbers (%).